AMG National Trust Bank Sells 7,350 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

AMG National Trust Bank cut its holdings in Perspective Therapeutics, Inc. (NYSE:CATX) by 19.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,980 shares of the company’s stock after selling 7,350 shares during the period. AMG National Trust Bank’s holdings in Perspective Therapeutics were worth $92,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CATX. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at about $153,000. WealthPlan Investment Management LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at about $4,530,000. Victory Capital Management Inc. raised its stake in shares of Perspective Therapeutics by 328.7% during the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock valued at $674,000 after acquiring an additional 38,690 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of Perspective Therapeutics during the third quarter valued at about $259,000. 54.66% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday. They issued a “sector outperform” rating and a $15.00 price target for the company. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $15.13.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $2.61 on Monday. Perspective Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $19.05. The firm’s 50-day simple moving average is $3.21 and its two-hundred day simple moving average is $7.66.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.